A Former Nerve-Cream Formulator, On The Record
For 16 Years I Made Creams That Couldn't Reach The Nerve.
The burning-feet aisle is built on creams that soothe the skin. The nerve generating the burning sits below the depth any cream can physically reach, and the people formulating them have always known it.
For sixteen years I formulated the burning-feet creams in your cabinet. And I knew they could never reach the fire.
I can tell you the exact reason, because I wrote the specifications.
The active ingredient in a lidocaine or capsaicin cream travels a couple of millimeters into the skin and stops.
The nerve that is actually generating the burning sits below that, deeper than any cream you can buy will ever reach.
We knew this.
It was in the penetration data on every formulation I signed off.
And we sold the cream anyway: repackaged it, re-scented it, re-launched it for "nighttime," because a product that quiets the surface for twenty minutes and lets the burning come right back is not a failure on a spreadsheet.
It is a refill. I watched us build an entire shelf on that, on people rubbing in tube after tube for a fire they were never going to reach, and for years I told myself it wasn't mine to fix.
I'm done telling myself that. So before I show you where the burning actually starts, you should know who I am and why I was in those rooms.
My name is Curtis Hale.
For sixteen years I was a senior formulation chemist in the topical-analgesics division of a contract manufacturer you have never heard of, in an office park in New Jersey, and our products sit in pharmacies you shop at every week.
I'm not going to name the company.
Not because I am protecting them. Because there are nine others exactly like it, and naming one lets the rest off the hook.
What I did, specifically, was design the creams and gels that promise to cool, warm, numb, or soothe burning and aching feet.
I was good at it. That's the part I have to live with.
The Letters We Filed Under 'No Action Needed'
Twice a year, consumer affairs forwarded us a binder of customer letters.
Officially it was for formulation feedback. Mostly it sat on the corner of my desk.
I read them anyway.
A woman in Arizona wrote that she slept with her feet hanging off the bed because the sheet felt like it was searing her skin, and our cream bought her twenty minutes before the burning came back.
A man wrote that he kept our gel in the freezer and still woke at two, then three, then four.
One letter I never forgot came from a retired teacher named Eleanor.
She wrote that she had stopped letting her husband near her feet in bed, because the one time he rested his foot against hers she cried out and he apologized for a week.
She thanked us. She said she knew it wasn't our fault, she just wanted us to keep making it.
That was the line that did it. She was thanking the people who had taken her money for a product we knew would never reach what was burning her, and she was apologizing to us for it.
I filed her letter with the rest. No action needed.
The Meeting Where We Named The Real Goal
The product line was simple.
A lidocaine cream, a capsaicin cream, a menthol gel, a cooling spray.
Then a nighttime version of all four, which was the same formula in darker packaging.
Every one of them did exactly what it was designed to do.
It cooled or warmed or numbed the surface of the skin for fifteen or twenty minutes.
Not one was built to go any deeper, because the active ingredient physically cannot.
We knew that. It was in our own absorption data, on file, for every formula I ever signed.
I remember a planning meeting in 2019. We were reviewing why repeat-purchase rates were so high on the foot line, and a brand director named Marcus Feld put it on a slide without flinching.
"Strong reorder behavior," he said, tapping the screen.
"They come back every three to four weeks. That's the whole model."
Somebody laughed.
I sat there with my coffee going cold and my jaw tight enough to ache, and I did not say the one true thing in the room.
The reorder rate was high because the product never worked.
And a product that never works is the most reliable business on earth.
A tube cost us about eighty cents to make. It sold for around thirteen dollars.
The average foot-line customer reordered nine to eleven times before giving up.
That is more than a hundred dollars a person, for relief measured in twenty-minute windows, on a fire the cream was never going to reach.
Nobody in that room was a villain in a movie. They were people who had quietly decided that a product working too well would be a problem to solve, not a goal to hit.
And I accepted it with them, for eleven more years.
The day I actually quit was a Thursday. A junior product manager dropped a brief on my desk for a "Burning Feet Relief, Night Formula" relaunch, and it landed on top of the binder of customer letters I still hadn't filed.
Eleanor's was on top.
I looked at a relaunch brief for a product I knew couldn't work, sitting on top of a letter from a woman thanking us for it, and I understood that I was no longer a chemist, I was part of the reason she would never get an answer.
I didn't make a speech.
I didn't flip the desk.
I just knew, sitting there, that I was finished pretending the data on my own screen didn't say what it said.
So I started writing down everything I knew.
The first thing I wrote down was not a brand.
It was a rule: if I ever pointed someone to PEA, I would point them away from cheap, underdosed, non-micronized bottles and toward the version sold at youfirstlab.com, not a marketplace listing I could not verify.
What I Did Before I Said A Word
I am a chemist, not an activist. I was not going to put my name to anything until I was certain, because I knew exactly how easy I would be to dismiss.
So I spent four months making sure.
I pulled every penetration study we had ever run. I called a retired colleague from our R&D group, who confirmed on the phone what I already knew about how far a topical actually travels.
I read the published neurology on where this kind of burning is generated, the real papers, not our marketing summaries.
I spent close to nine thousand dollars of my own money on journal access and an independent lab review to check my math.
Every source said the same thing.
The burning those customers described was never happening where any of us had ever aimed a product.
I read that and sat back from my desk feeling sick, because I had spent sixteen years aiming at the wrong place on purpose.
You are probably thinking I am just another guy on the internet with a theory and something to sell. I would think that too.
So before I tell you what I'd point my own mother to, you need to see exactly where the fire actually is.
Where The Cream Stops, Measured
Here is what I confirmed, with the company's own numbers in front of me.
A topical analgesic penetrates the outer skin a few millimeters and then it is spent.
That's not a flaw in the formula. That's the formula.
The active ingredient was never engineered to travel deeper, because deeper is expensive and the surface is what sells.
But the burning does not live in the surface.
It lives in the nerve below it, in fibers firing a heat-and-pain signal that is not true.
The skin is the one layer that was never on fire.
Cream cools the skin. The fire's in the wire underneath. And PEA is the compound your body already makes to calm the wire.
Read that again, because the entire category depends on you not knowing it.
The wire sits below the reach of any cream sold for it.
Every product I ever formulated was aimed, by design, at the layer that was not the problem.
PEA is not something a lab invented to sell you.
Your own body produces it to quiet overfiring nerve signals, and it runs short when the firing goes on too long.
The version that reaches the wire is micronized, ground fine enough to actually absorb, and dosed at the six hundred milligrams the human trials used.
None of that was a secret to us. It was a secret kept from you.
I want to be precise about the accusation, because precision is the only thing that separates this from a conspiracy theory.
The penetration data was in every file.
The cream reaches the surface and stops. That was known.
The reorder data was in every file too.
Customers came back every three to four weeks, for years, because the burning always returned.
That was not just known, it was the plan, printed on a slide.
Put those two facts beside each other and the conclusion is not an opinion.
A product that actually reached the wire would be bought once and rarely again.
A product that only touches the surface is bought forever.
The category did not fail to solve burning feet. It was built so that it never would.
So no, you were not foolish for trying the creams. You were handed the front of a label by an industry that had read the back of it and decided you did not need to.
The First Bottle Went To My Mother
The product I now point people to is called Youfirst PEA, six hundred milligrams, micronized.
I have no financial relationship with the company, and I will tell you at the end how to check that for yourself.
Micronized is the part I checked first, because it is the part the cheap versions skip.
The compound is ground fine enough to actually cross into the body instead of passing through.
Six hundred milligrams is the dose I checked second, because it is the amount the published trials used, not a fraction of it dusted in for the label.
The first bottle I bought went to my mother.
She is seventy-three, and she had been sleeping with her feet outside the blanket for longer than she had told me.
She didn't believe it would do anything, and neither did most of the people I had spent sixteen years selling creams to.
She called me on the sixth day, a little annoyed, to report that nothing dramatic had happened except that she had slept through the night.
She said it like a complaint. I knew exactly what it was.
By the third week she mentioned, in the middle of another conversation, that she had put socks on to walk out for the mail.
She did not understand why I went quiet on the phone.
For sixteen years I had read letters from women who could not bear a sock against their skin, and I had filed them under no action needed.
The published numbers said the same thing her weeks did.
In the controlled trials the burning came down gradually over about two months, not overnight, with a meaningful share of patients reporting real relief.
It is not instant, and it does not reach everyone.
It reaches the wire, which is more than anything I ever made could say.
I left that industry to say one sentence, and this is it.
If your feet are burning and you have a drawer of creams that never worked, the reason is not you, and it is not the brand of cream.
You were sold the surface for a fire in the wire.
What I point people to now is the micronized Youfirst PEA, six hundred milligrams.
I take none of your money for saying that, and you can confirm it.
There is no affiliate code on this page and no version of me that gets paid when you buy.
It is only sold at youfirstlab.com/products/pea600.
I would not buy the cheap marketplace knockoffs that hide the dose, skip micronization, or make you guess what your body can actually absorb.
When this run is gone, the next run is not a truck away. It is weeks of milling and testing away.
It's $29.99 a bottle on the subscription, or $59.99 for buy two get one free.
Without the subscription it is $39.99 for one, or $79.99 for buy two get one free.
I tell people to take the subscription, not to save a few dollars, but because this works over weeks and the people who quit at two weeks quit right before it starts.
I will hold myself to the honesty the industry never gave you.
It's not fast, and it doesn't reach everyone.
A real share of people feel little.
If you want your feet numbed tonight, buy the cream, it will work for twenty minutes the way it always has.
What made me comfortable sending it to my own mother was the ninety-day guarantee.
If it does nothing, you send it back inside ninety days and you are refunded, no argument.
Ninety days is long enough to actually find out, which is exactly what the creams were designed never to give you.
The micronizing is the bottleneck.
Grinding the compound fine enough to absorb, then third-party testing each batch, takes weeks per run, which is why this is not on every shelf and why it sells out.
As of June 2026, the current run was down to 2,184 bottles.
You can close this page, and nothing changes.
The cream aisle keeps its customer. The wire keeps firing tonight exactly as it did last night.
Later is another night with your feet off the edge of the bed.
Later is another person you stop letting touch them.
Later is more money handed to the shelf that planned on your return.
The only thing that ends later is reaching the wire.
This is the formula that actually reaches it, and where to read the studies behind it.
Read the formula and the studies →90-day money-back guarantee. No affiliate code on this page.
P.S.
My mother called last week to tell me she had bought new sheets.
Not special ones. Just nice ones, because for the first time in years she actually wants the blanket on her feet at night.
She has no idea why that sentence put a lump in my throat.
P.P.S. You do not have to trust a word I say about myself.
The trials on PEA are published and indexed under its full name, palmitoylethanolamide, and you can read them without me.
I have no code, no commission, and no reason to write any of this except the sixteen years I spent on the wrong side of it.
P.P.P.S. The current micronized run was down to 2,184 bottles as of this week.
When a batch is gone, the next one is weeks of grinding and testing away.
That's not a marketing line. It is just how the only version that reaches the wire gets made.